TELA Bio to Announce Second Quarter 2023 Financial Results and Confirms Participation in the Canaccord Genuity 43rd Annual Growth Conference
July 26 2023 - 7:00AM
TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage
medical technology company focused on providing innovative
soft-tissue reconstruction solutions that optimize clinical
outcomes by prioritizing the preservation and restoration of the
patient's own anatomy, today announced that the Company will report
second quarter 2023 financial results on Wednesday, August 9, 2023.
TELA Bio’s management will host a conference call and webcast at
4:30 p.m. ET that day to discuss the financial results and provide
a corporate update.
Second Quarter Earnings Conference Call and Webcast
DetailsInvestors interested in listening to the conference
call should register online. Participants are required to register
a day in advance or at minimum 15 minutes before the start of the
call. A replay of the webcast can be accessed via the Events &
Presentations page of the investor section of TELA's website.
Canaccord Genuity Growth
ConferenceAdditionally, TELA Bio today announced that it
will participate in the upcoming Canaccord Genuity 43rd Annual
Growth Conference in Boston, MA. Management is scheduled to present
on Thursday, August 10th, at 9:00 a.m. ET. Interested parties can
access the live and archived webcast of the presentation on the
Investors section of the TELA Bio website at ir.telabio.com.
About TELA Bio, Inc.TELA Bio, Inc. (NASDAQ:
TELA) is a commercial-stage medical technology company focused on
providing innovative technologies that optimize clinical outcomes
by prioritizing the preservation and restoration of the patient's
own anatomy. The Company is committed to providing surgeons with
advanced, economically effective soft-tissue reconstruction
solutions that leverage the patient's natural healing response
while minimizing long-term exposure to permanent synthetic
materials. For more information, visit www.telabio.com.
Caution Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations are forward-looking statements and reflect the current
beliefs of TELA Bio's management. These statements are not
guarantees of future performance and are subject to certain risks,
uncertainties and other factors that could cause actual results and
events to differ materially and adversely from those indicated by
such forward-looking statements. These risks and uncertainties are
described more fully in the "Risk Factors" section and elsewhere in
our filings with the Securities and Exchange Commission and
available at www.sec.gov, including in our Annual Report on Form
10-K and Quarterly Reports on Form 10-Q. Any forward-looking
statements that we make in this announcement speak only as of the
date of this press release, and TELA Bio assumes no obligation to
update forward-looking statements whether as a result of new
information, future events or otherwise after the date of this
press release, except as required under applicable law.
Investor ContactGreg
Chodaczek347-620-7010ir@telabio.com
TELA Bio (NASDAQ:TELA)
Historical Stock Chart
From Apr 2024 to May 2024
TELA Bio (NASDAQ:TELA)
Historical Stock Chart
From May 2023 to May 2024